The most consequential prices in American healthcare are often the ones patients never see.
Prescription drug pricing appears legible on the surface—copays printed on receipts, benefit designs described in tidy actuarial tables—but the machinery beneath those numbers remains stubbornly opaque. Within that machinery lies the National Average Drug Acquisition Cost database, quietly published by the Centers for Medicare & Medicaid Services and documented through the agency’s https://www.medicaid.gov/medicaid/prescription-drugs/pharmacy-pricing/index.html. The dataset was created for Medicaid reimbursement policy, not for public interpretation. Yet the numbers it contains offer one of the few systematic glimpses into what pharmacies actually pay to acquire medications from wholesalers.
That distinction matters. It alters the frame through which prescription drug prices are understood.
Most consumer drug‑price tools track retail cash prices or negotiated coupon discounts. Platforms such as https://www.goodrx.com or <https://www.pharmacychecker.com> collect prices from pharmacies themselves or from consumer‑facing price files. These numbers reflect the visible retail layer of the market—the price that appears at the counter or on a coupon card. NADAC operates further upstream. The dataset approximates the invoice prices paid by pharmacies to wholesalers, derived from voluntary surveys and updated weekly. It is, in other words, a proxy for the acquisition side of the pharmacy supply chain.
Tools such as MedPricer.org attempt to surface those acquisition benchmarks to clinicians, patients, and journalists who rarely encounter them in ordinary practice. The concept is disarmingly simple: if a pharmacy’s acquisition cost is known—or at least approximated—then some of the arithmetic behind prescription drug reimbursement becomes visible. But the implications of that visibility are less straightforward than they first appear.
Transparency, after all, is not neutral.
The NADAC dataset emerged from a long history of disputes over Medicaid pharmacy reimbursement formulas. Earlier benchmarks—most famously Average Wholesale Price—were widely criticized for drifting far from the prices pharmacies actually paid. Litigation in the early 2000s revealed how those benchmarks had become inflated through manufacturer‑reported figures, leading to systematic overpayment by public programs. The creation of NADAC was meant to anchor reimbursement to something closer to reality. CMS began publishing the data openly, along with methodological documentation available through the agency’s survey program at <https://www.medicaid.gov/medicaid/prescription-drugs/pharmacy-pricing/survey-of-retail-prices/index.html>.
Yet NADAC was never designed as a consumer‑facing transparency tool. Its purpose was administrative. The database functions primarily as a reimbursement reference for Medicaid programs determining pharmacy payment rates. The numbers represent averages derived from voluntary pharmacy surveys. They exclude certain purchasing arrangements. They lag behind market fluctuations. And they exist within a regulatory framework that assumes the data will be interpreted by policymakers rather than patients.
Once the dataset escapes that administrative context, its meaning changes.
Consider the moment a patient standing at a pharmacy counter discovers that the medication in their hand carries three prices simultaneously: the acquisition benchmark implied by NADAC, the negotiated reimbursement set by a pharmacy benefit manager, and the copay dictated by their insurance plan. The relationship between those figures can be surprising. Sometimes the patient’s insurance copay exceeds the acquisition cost implied by the NADAC benchmark. Sometimes the opposite occurs. Sometimes the numbers diverge so widely that the structure of the reimbursement contract becomes the only plausible explanation.
Such discoveries do not necessarily reveal wrongdoing. They reveal structure.
The prescription drug supply chain has evolved into a complex system of contractual flows. Pharmacy benefit managers negotiate reimbursement rates with pharmacies and rebates with manufacturers. Pharmacies purchase inventory through wholesalers operating under distribution agreements. Insurers design benefit tiers intended to shape utilization patterns. Each layer of that architecture produces prices that are internally rational yet externally confusing. A patient confronting the system encounters fragments rather than the full model.
Data transparency platforms intervene by assembling those fragments into comparative views. In theory, a tool that juxtaposes NADAC benchmarks against retail prices allows users to infer something about the margin structure embedded in pharmacy reimbursement. In practice, the exercise introduces new ambiguities.
NADAC reflects average acquisition costs reported by a subset of pharmacies. Independent pharmacies may purchase through group purchasing organizations that yield lower prices than the benchmark. Chain pharmacies may negotiate different discounts through scale. Specialty medications often fall outside the dataset entirely. Even within the NADAC methodology, methodological notes caution readers against interpreting the figures as precise purchase prices. The survey’s documentation emphasizes sampling variability and the limits of voluntary reporting.
Transparency therefore arrives with an interpretive burden.
Journalists exploring prescription drug economics occasionally encounter NADAC when investigating reimbursement disparities. Analysts at the Peterson‑KFF Health System Tracker have noted long‑term growth in prescription drug spending in analyses such as <https://www.healthsystemtracker.org/chart-collection/recent-forecasted-trends-prescription-drug-spending/>. Those macro‑level trends obscure the micro‑level arithmetic that occurs at individual pharmacy counters every day. NADAC, while imperfect, provides a bridge between those scales. It links the abstract economics of pharmaceutical spending to the mundane transaction of dispensing a prescription.
But transparency also reshapes incentives.
If acquisition benchmarks become widely visible, pharmacies may find themselves explaining margins that were previously invisible to patients. Pharmacy benefit managers may encounter new scrutiny around reimbursement formulas that depend on opaque spread pricing arrangements. Insurers may confront questions about copay structures that bear little relationship to underlying acquisition costs. Each actor in the supply chain can plausibly defend their position. Yet the collective effect of transparency may be to expose tensions that were previously absorbed quietly by the system’s complexity.
There is precedent for this dynamic.
Financial markets have long wrestled with the paradox of transparency. When certain price signals become widely visible, participants adjust behavior in ways that reshape the very benchmarks being revealed. The publication of acquisition costs may influence how pharmacies negotiate purchasing contracts. Manufacturers may reconsider pricing strategies if wholesale benchmarks become more widely scrutinized. Pharmacy benefit managers might adapt reimbursement formulas to account for the interpretive narratives that transparency tools enable.
None of these responses would necessarily reduce drug spending. They might merely redistribute it.
The question, then, is not whether transparency improves the system but what kind of system transparency produces. Data visibility can empower investigative journalism, patient advocacy, and employer‑based benefit analysis. It can also simplify narratives that obscure the contractual complexity underlying pharmaceutical markets. Numbers, once extracted from their administrative context, acquire rhetorical force.
MedPricer.org operates within this tension. By presenting NADAC benchmarks alongside retail pricing signals, the platform implicitly invites users to interpret disparities between acquisition cost and patient price. Sometimes the interpretation leads to meaningful insights about supply chain dynamics. Sometimes it simply reveals how little a single dataset can explain about a market defined by overlapping contracts and regulatory constraints.
Transparency tools therefore function less as solutions than as instruments of inquiry.
They expose the architecture of the drug pricing system without fully explaining it. They offer glimpses into the economics of pharmaceutical distribution while leaving large portions of the structure unobserved. And they remind clinicians, investors, and policymakers that the numbers guiding reimbursement decisions often originate in administrative datasets never intended for public scrutiny.
The paradox is that NADAC’s greatest value may lie not in the prices it reveals but in the questions those prices provoke.
